April 13, 2017 7:53am
Cell therapy’s biggest losers – lately, shareholders! As they leave, trial subjects will be left out of a research study which will get smaller and less powered.
Managements need to mount an offensive to lure back the disaffected, coddle the currents shareholders and then prove that they can deliver on share pricing or they will have lost the hearts and minds of investors
Also, don’t be dependent on some of those PR firms who shouldn’t be rowing on your boat as they provide the same old hype rhetoric and old fustian BS to only increase the wail of the shrills
Investors need to mobilize …!
Pre-open indications: five (5) – 2 SELLS, 3 BUYS
Critical information ahead of “our” universe’s open! I provide intelligence and analysis for short and near-term investment.
Readership is a team sport, are you on it?
Expectation is the word for 2017 – meeting the unknowns with the soon to be exposed concerns will be the subject of investing decisions throughout this year.
Dow futures are DOWN -0.14% and NASDAQ futures are DOWN -0.19%
U.S. stock index futures pointed to a lower open on Thursday after President Donald Trump said the dollar was getting "too strong."
European markets moved lower during mid-morning trade as investors digested U.S. President Donald Trump's comments that he would prefer the Fed to keep interest rates low and suggested the dollar is too strong.
Asian markets closed mixed, with Japanese shares dropping amid a stronger yen against the dollar.
Data docket: jobless claims and PPI released at 8:30 a.m. ET, with consumer sentiment set to come out at 10:00 a.m. ET.
The stem, cell, gene and regenerative therapy (SCG&RT) closed NEGATIVE on Wednesday and Tuesday, POSITIVE on Monday, Friday and last Thursday.
The SCG&RT sector’s record after the last 5 days (of 43 covered companies):
· Wednesday closed NEGATIVE with 21 decliners, 17 advancers and 5 flats;
· Tuesday closed NEGATIVE with 28 decliners, 13 advancers and 2 flats;
· Monday closed POSITIVE with 18 decliners, 23 advancers and 2 flats;
· Friday closed POSITIVE with 19 decliners, 21 advancers and 3 flats;
· Last Thursday closed POSITIVE with 16 decliners, 25 advancers and 2 flats;
Remembering Wednesday’s closing bell newsletter, “The sector ticks down … As volatility upticks.”
- Reiterating, “The tension of the oversold and the overbought is like elastic that stretches and constricts! Investors NEED a sense of the sector's priorities … other than depreciating and dilution financings.”
What did I see yesterday, <Wednesday> the sector’s buying and selling was managed through low volume except in a few cases:
· AXGN, and FCSC to the upside;
· ADRO, AGTC, AST, BLCM and CYTX to the downside
What else did I see?
Volume continued low, driving the advance/decline line as the negative closes declined slightly <28 to 21>.
Yesterday’s oversold continued to decline while the overbought also showed signs of weakness
Fundamentals and charts continue to reflect their toll;
The sector was slipping again on NO news.
Referencing the title, how many PR firms haven’t earned the monies paid to focus a TRUE response that places a value on a placement companies would like to get …
- The OLD reporting models are crap, as many PR firms have created a false narrative to hype and pollute the storyline.
PR firms’ usually only guarantee a placement on a newswire … and
- Are NOT on the front line of getting your message placed to the media principals – the serious blogs and outlets who are the tip of the spear of penetrating the algorithmic “wall” …
WHY, because you as a CEO haven’t done your job well enough to be listened to yet, a good part of the blame goes to your agency which hasn’t the capacity or the guts to tell you the truth of why!
- Is the reality so hard to handle ...?
Remember CEOs are judged by their share pricing, so - speak TO investors not AT them - IF they speak at all!
You’ve made it to the office, turned on the monitor, having just gotten your coffee and it hits you - what could be today’s trades?
Watch list:
· The iShares Nasdaq Biotechnology (IBB) closed Wednesday up +0.10% and is NOT indicating in Thursday’s pre-market;
· The SPDR S&P Biotech ETF (XBI) closed Wednesday up +0.48% and is NOT indicating in Thursday pre-market;
· The Health Care Select Sector SPDR ETF (XLV) closed flat at 0.00 Wednesday and is NOT indicating in Thursday’s pre-open;
· The iShares Russell 2000 (IWM) closed down -1.36% on Wednesday and was DOWN -0.12% Thursday’s pre-open
Companies in my headlights:
Applied Genetic Technologies (AGTC) closed down another -$0.25 to $6.05 after Tuesday’s $6.30 (-$0.10) post Monday’s $6.40 (-$0.10). AGTC is trading well below its cash value, the is approximately $8.53 in cash per share – Maintaining BUY;
Bellicum Pharma (BLCM) closed up +$0.09 to $12.95. The aftermarket indication is +$0.29 or +2.24% - BUY;
Juno therapeutics (JUNO) closed down -$0.09 to $23.70. The aftermarket indication is a negative -$0.34 or -1.43% - SELL;
Kite Pharma (KITE) closed up +$0.91 to $79.20. The pre-market indication was a negative -0.20 or -0.25% - SELL;
Verastem (VSTM) closed down -$0.12 to $1.62 following Tuesday’s $1.74 (-$0.05) after Monday’s $1.79 (-$0.04) post Friday’s $1.83 (+$0.06). Back to the basics, VSTM has $2.19 in cash per share and no debt thus trading below its cash value. The aftermarket indication was a positive +$0.14 to $1.76 – Maintaining BUY;
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
Henry’s comments are for informational purposes only and are not a substitute for personalized advice. Consult your advisor about what is best for you.
